Cyclosporin H Improves the Transduction of CD34 + Cells with an Anti-Sickling Globin Vector, a Possible Therapeutic Approach for Sickle Cell Disease
Human Gene Therapy · 2024
DOI: 10.1089/hum.2024.098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Mirella Mormin und 7 weiteren Autor:innen. Beteiligte Einrichtung: ART-TG, Inserm US35, Corbeil-Essonnes, France. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Vectors, Transduction, Genetic, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ART-TG, Inserm US35, Corbeil-Essonnes, France.
- Maternity/Obstetrics Unit, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France.
- Institute Imagine, Inserm, Hopital Necker-Enfants Malades, Paris, France.
ORCID-Profile: Anne Galy
Zitieren
APA
Mormin, M., Rigonnot, L., Chalumeau, A., Miccio, A., Fournier, C., Pajanissamy, S., Dewannieux, M., & Galy, A. (2024). Cyclosporin H Improves the Transduction of CD34 + Cells with an Anti-Sickling Globin Vector, a Possible Therapeutic Approach for Sickle Cell Disease. Human Gene Therapy. https://doi.org/10.1089/hum.2024.098
Vancouver
Mormin M, Rigonnot L, Chalumeau A, Miccio A, Fournier C, Pajanissamy S, et al. Cyclosporin H Improves the Transduction of CD34 + Cells with an Anti-Sickling Globin Vector, a Possible Therapeutic Approach for Sickle Cell Disease. Human Gene Therapy. 2024. doi:10.1089/hum.2024.098
BibTeX
@article{Mormin2024,
author = {Mormin, Mirella and Rigonnot, Luc and Chalumeau, Anne and Miccio, Annarita and Fournier, Clémence and Pajanissamy, Sandya and Dewannieux, Marie and Galy, Anne},
title = {Cyclosporin H Improves the Transduction of CD34 + Cells with an Anti-Sickling Globin Vector, a Possible Therapeutic Approach for Sickle Cell Disease},
journal = {Human Gene Therapy},
year = {2024},
doi = {10.1089/hum.2024.098}
}
EUVIMED